The recipients of ESC‐MSC‐CM + MGO developed liver dysfunction with significantly lower ALT, AST and ALP liver enzyme levels compared to the groups that received either ESC‐MSC‐CM or MGO (Figure 2b). This evidence concerns the gene GPT and Decreased liver function.